AR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
AR is not a clear buy right now for a beginner long-term investor with $50,000-$100,000. The business fundamentals are strong and analyst sentiment is broadly bullish, but the current price is sitting right on support with weak short-term momentum, heavy bearish options positioning, and insider selling. Since the user is impatient and does not want to wait for a better entry, my direct view is to hold off and not initiate a fresh buy at this exact level.
The trend is mixed. Short-term momentum is weak: MACD histogram is negative and expanding, which points to near-term downside pressure. RSI_6 is 26.743, indicating the stock is oversold, but not yet confirming a durable reversal. The moving averages are constructive because SMA_5 > SMA_20 > SMA_200, so the broader trend is still bullish. Price at 36.36 is almost exactly at S1 support (36.324), with downside room to S2 at 35.274 and upside resistance at R1 39.724. Overall, this looks like a stock in a healthy long-term uptrend but with near-term weakness and limited immediate upside confirmation.
Q1 2026 financials were very strong: revenue rose 34.10% YoY, net income rose 157.35% YoY, EPS rose 160.61% YoY, and gross margin improved to 41.32%. Analysts have also been lifting targets across the board, with UBS, Jefferies, BofA, Morgan Stanley, Citi, and others raising price targets and keeping mostly Buy/Overweight ratings. Jefferies highlighted constructive demand for U.S. natural gas and NGLs, and management reportedly improved synergy targets and lowered cash cost guidance. The stock also remains above its 200-day moving average, which supports the longer-term trend.
Insiders are selling, and the selling amount increased 374.34% over the last month. Officer Kennedy Michael N. plans to sell 185.83K shares worth about $7.31 million. Options positioning is heavily bearish, with strong put demand. The technical setup is also weak in the short term, with a negative MACD histogram and price hovering near support. Similar-pattern analysis suggests negative forward returns over the next week and month.
In Q1 2026, AR posted strong growth across the board. Revenue increased to $1.91 billion, up 34.10% year over year. Net income rose to $535.2 million, up 157.35% YoY. EPS increased to $1.72, up 160.61% YoY. Gross margin improved to 41.32%, up 29.73% YoY. These results show strong operational and profitability momentum in the latest quarter season.
Wall Street sentiment is mostly positive. Multiple firms raised price targets recently: UBS to $56, Jefferies to $57, BofA to $44, Siebert Williams to $56, Morgan Stanley to $56, Citi to $53, and Jefferies earlier to $54. Most maintain Buy or Overweight ratings, while Roth Capital remains Neutral with a $38 target. Pros: improving natural gas/NGL outlook, strong cash flow potential, and better synergy/cost guidance. Cons: one neutral view after Q1 and the stock still trades well below several bullish targets, indicating the market has not fully confirmed the upside yet.
